Dr Reddy's Laboratories

Nomura's upgrade to 'Buy' lifts Dr Reddy's share over 4% in weak market

The northward move in Dr Reddy's share price came after Tokyo, Japan-based brokerage Nomura upgraded the stock to 'Buy' from 'Neutral'

Dr Reddy's launches Toripalimab to treat nasopharyngeal cancer in India

In 2023, Dr Reddy's signed a licensing and commercialisation agreement with Shanghai Junshi Biosciences for Toripalimab

Dr Reddy's Labs Q2 Preview: Profits may decline 7%, revenues to rise 12%

Analysts expect Dr Reddy's Labs to report a single digit fall in profits with a double digit revenue growth

Dr Reddy's completes acquisition of Haleon's global NRT portfolio

DRL's Swiss subsidiary completed the acquisition through the purchase of shares of Northstar Switzerland SARL, a Haleon group company

Dr Reddy's gets USFDA's inspection report for Srikakulam-based API plant

Dr Reddy's Laboratories on Friday said it has received the establishment inspection report (EIR) from the US health regulator for its active pharmaceutical ingredient manufacturing facility (CTO-6) in Srikakulam, Andhra Pradesh. The US Food and Drug Administration (USFDA) has classified the inspection as Voluntary Action Indicated (VAI) and concluded that the inspection is close, the Hyderabad-based drug maker said in a statement. As per USFDA, VAI means that objectionable conditions or practices were found, but the agency is not prepared to take or recommend any administrative or regulatory action. On June 7 this year, Dr Reddy's had stated that the US health regulator has issued Form 483 with four observations after inspecting its Srikakulam-based facility. Shares of the company on Friday ended 0.42 per cent down at Rs 6,669.75 apiece on the BSE.

Dr Reddy's, Lupin recall products in US due to manufacturing issues: USFDA

Dr Reddy's Laboratories and Lupin are recalling products in the US due to manufacturing issues, as per the US Food and Drug Administration (USFDA). Dr Reddy's Laboratories Inc, a subsidiary of Hyderabad-based drug firm, is recalling Ibuprofen tablets in multiple strengths, the US health regulator said in its latest enforcement report. Ibuprofen tablets are indicated for pain relief and fever. New Jersey-based Dr Reddy's Laboratories Inc. is recalling 1,03,298 bottles (800 mg); 31,802 bottles (600 mg); and 14,940 bottles (400 mg) of Ibuprofen tablets in the US market, USFDA said. The company is recalling the affected lot due to "Failed impurities/degradation specifications," it added. "Results for unknown impurity were 0.13 per cent and 0.11 per cent, respectively, exceeding the 0.10 per cent specification limit," USFDA noted. The company initiated the Class II nationwide recall on August 6 this year. USFDA stated that Lupin is recalling 4,554 bottles of Cefixime for Oral Suspen

Dr Reddy's Labs Q1 Preview: Market share loss in products to drag profits

Indian drugmaker, Dr Reddy's Laboratories is all set to deliver its financial performance for the first quarter of financial year 2024-25 (Q1FY25) on Saturday, July 27, 2024

Dr Reddy's Lab pushes the pedal to touch 1.5 billion patients by FY30

The company also announced that it will work together with the United States Food and Drug Administration (USFDA) to launch the biosimilar rituximab in the US

Earnings boost for Dr Reddy's Lab post consumer healthcare acquisition

In India, DRL has an OTC portfolio in the hydration, cough-cold-allergy, and skin care categories

Dr. Reddy's to acquire Haleon's nicotine replacement biz for 500 mn pounds

The acquisition includes Nicotinell, a global leader in the NRT category, and its local market-leading brand names Nicabate, Habitrol, and Thrive

Stocks to Watch, June 14: Voda Idea, Dr Reddy's, Suzlon, Signature Global

Stocks to Watch on Friday, June 14: Vodafone Idea (Vi) has decided to offer a Rs 2,458 crore stake to long-term vendors Nokia and Ericsson in a bid to partially clear outstanding dues

Buzzing stocks, June 10: Order boost for KEC, RVNL; USFDA action on DRL

Stocks to Watch on Monday, June 10: RVNL's joint venture with KRDCL has emerged as the lowest bidder for a project worth Rs 156 crore

Dr Reddy's Laboratories eyes acquisitions to drive growth in India

The share of chronic has been steadily rising in the Rs 2 lakh crore domestic pharma market- from 36.4 percent in January 2022 to 38.1 percent in January 2024

Dr Reddy's Q4 results: Net profit rises 36% to Rs 1,307 cr, revenue up 12%

Q4FY24 results: The company board has recommended a final dividend of Rs 40 per equity share of Rs 5 each for the financial year 2023-24

Dr Reddy's Q4 Preview: Here's what key brokerages expect from its results

Indian pharmaceutical giant Dr Reddy's Laboratories is set to witness a single to double digit growth in sales on a year-on-year (Y-o-Y) basis for the fourth quarter of financial year 2023-24 (Q4FY23)

Nestle India Q4FY24 results: Net profit soars 27% to Rs 934 crore

Company to launch Nespresso in India, announces joint venture with Dr. Reddy's Laboratories

Dr Reddy's to market Bayer's second brand of heart failure drug in India

Under the agreement, Dr Reddy's will market Vericiguat under the brand name Gantra

Market resilience in a pill: Pharma's formula for Q3 earnings upgrades

Rx for returns: Pharma firms' dominance in market recovery prescription

Dr Reddy's rallies 4%; market cap touches Rs 1 trillion post Q3 results

With this, Dr Reddy's has become the third listed pharmaceutical company to achieve the Rs 1-trillion m-cap feat

Dr Reddy's launches wearable device for drug-free management of migraine

In January this year, Dr Reddy's entered an exclusive agreement with Theranica for the marketing and distribution of Nerivio in India